# Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

> **NCT00602082** · PHASE2 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 84 (estimated)

## Conditions studied

- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor

## Interventions

- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** streptozocin
- **GENETIC:** DNA analysis
- **GENETIC:** RNA analysis
- **GENETIC:** protein analysis
- **GENETIC:** proteomic profiling
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00602082
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602082, "Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00602082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*